Korea's Health Ministry Dismisses Likelihood Of Compulsory Licensing For Antivirals Tamiflu and Relenza
This article was originally published in PharmAsia News
Executive Summary
SEOUL - The South Korean government is not in a "desperate position" that would justify seeking compulsory licensing to secure more of Roche's Tamiflu (oseltamivir) and GlaxoSmithKline's Relenza (zanamivir) in a protracted battle against A/H1N1, the health ministry said
You may also be interested in...
Korea Extends Closely Watched Pilot Project For Rare Disease Drug Refunds Three More Years
To maintain a stable supply of some multinational products for patients with rare diseases, the health ministry has extended its pilot refund system for three more years until 2015.
Korea FDA Issues Approval To Chong Kun Dang For Future Sales Of Generic Tamiflu
SEOUL - The Korea Food & Drug Administration granted approval to local South Korean Chong Kun Dang Pharmaceutical to sell its generic version of Roche's Tamiflu (oseltamivir) at some point in the future
Korea FDA Issues Approval To Chong Kun Dang For Future Sales Of Generic Tamiflu
SEOUL - The Korea Food & Drug Administration granted approval to local South Korean Chong Kun Dang Pharmaceutical to sell its generic version of Roche's Tamiflu (oseltamivir) at some point in the future